KR101263225B1 - 설사－우세형 및 교대형 과민성 장 증후군의 치료를 위한 카파－아편제 작용제 - Google Patents

설사－우세형 및 교대형 과민성 장 증후군의 치료를 위한 카파－아편제 작용제 Download PDF

Info

Publication number
KR101263225B1
KR101263225B1 KR1020127010007A KR20127010007A KR101263225B1 KR 101263225 B1 KR101263225 B1 KR 101263225B1 KR 1020127010007 A KR1020127010007 A KR 1020127010007A KR 20127010007 A KR20127010007 A KR 20127010007A KR 101263225 B1 KR101263225 B1 KR 101263225B1
Authority
KR
South Korea
Prior art keywords
ibs
pain
pharmaceutical composition
treatment
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020127010007A
Other languages
English (en)
Korean (ko)
Other versions
KR20120058614A (ko
Inventor
앨런 맨겔
Original Assignee
티오가 파마슈티칼스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 티오가 파마슈티칼스, 인코포레이티드 filed Critical 티오가 파마슈티칼스, 인코포레이티드
Publication of KR20120058614A publication Critical patent/KR20120058614A/ko
Application granted granted Critical
Publication of KR101263225B1 publication Critical patent/KR101263225B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
KR1020127010007A 2007-03-30 2008-03-07 설사－우세형 및 교대형 과민성 장 증후군의 치료를 위한 카파－아편제 작용제 Expired - Fee Related KR101263225B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92084107P 2007-03-30 2007-03-30
US60/920,841 2007-03-30
PCT/US2008/056317 WO2008121496A1 (en) 2007-03-30 2008-03-07 Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020097022558A Division KR101208326B1 (ko) 2007-03-30 2008-03-07 설사-우세형 및 교대형 과민성 장 증후군의 치료를 위한 카파-아편제 작용제

Publications (2)

Publication Number Publication Date
KR20120058614A KR20120058614A (ko) 2012-06-07
KR101263225B1 true KR101263225B1 (ko) 2013-05-13

Family

ID=39795494

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020127010007A Expired - Fee Related KR101263225B1 (ko) 2007-03-30 2008-03-07 설사－우세형 및 교대형 과민성 장 증후군의 치료를 위한 카파－아편제 작용제
KR1020097022558A Expired - Fee Related KR101208326B1 (ko) 2007-03-30 2008-03-07 설사-우세형 및 교대형 과민성 장 증후군의 치료를 위한 카파-아편제 작용제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020097022558A Expired - Fee Related KR101208326B1 (ko) 2007-03-30 2008-03-07 설사-우세형 및 교대형 과민성 장 증후군의 치료를 위한 카파-아편제 작용제

Country Status (19)

Country Link
US (2) US7960429B2 (enExample)
EP (3) EP2136801B1 (enExample)
JP (2) JP5416085B2 (enExample)
KR (2) KR101263225B1 (enExample)
CN (2) CN102641265A (enExample)
AU (1) AU2008232954A1 (enExample)
BR (1) BRPI0809651A2 (enExample)
CA (1) CA2682608A1 (enExample)
CY (1) CY1113317T1 (enExample)
DK (1) DK2136801T3 (enExample)
ES (1) ES2393815T3 (enExample)
HR (1) HRP20120798T1 (enExample)
IL (1) IL201226A0 (enExample)
MX (1) MX2009010409A (enExample)
PL (1) PL2136801T3 (enExample)
PT (1) PT2136801E (enExample)
RU (1) RU2441655C2 (enExample)
SI (1) SI2136801T1 (enExample)
WO (1) WO2008121496A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682608A1 (en) 2007-03-30 2008-10-09 Tioga Pharmaceuticals, Inc. Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome
US9303027B2 (en) 2010-07-19 2016-04-05 Dr. Reddy's Laboratories Ltd. Kappa opioid receptor agonists
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
CA3178035A1 (en) 2012-12-24 2014-07-03 Neurogastrx, Inc. Methods for treating gi tract disorders
US9844554B2 (en) 2014-06-24 2017-12-19 Neurogastrx, Inc. Prodrugs of metopimazine
JP6410641B2 (ja) 2015-03-04 2018-10-24 ローム株式会社 ワイヤレス送電装置、異物検出方法、充電器
US11246905B2 (en) 2016-08-15 2022-02-15 President And Fellows Of Harvard College Treating infections using IdsD from Proteus mirabilis
WO2018119108A1 (en) 2016-12-21 2018-06-28 Tioga Pharmaceuticals Inc. Splid pharmaceutical formulations of asimadoline
WO2019122361A1 (en) 2017-12-22 2019-06-27 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Asimadoline for use in treating pulmonary diseases, vascular diseases, and sepsis
US20200022974A1 (en) 2018-07-23 2020-01-23 Trevi Therapeutics, Inc. Treatment of chronic cough, breathlessness and dyspnea
MX2022008554A (es) 2020-01-10 2022-08-10 Trevi Therapeutics Inc Metodos de administracion de nalbufina.
EP4121083A4 (en) * 2020-03-18 2023-11-29 Cara Therapeutics, Inc. OLIGOSACCHARIDE FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
EP3932390A1 (en) 2020-07-02 2022-01-05 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical gel formulation containing asimadoline
WO2022085736A1 (ja) * 2020-10-20 2022-04-28 協和化学工業株式会社 診療支援装置、診療支援方法及び診療支援プログラム
WO2022155332A1 (en) * 2021-01-13 2022-07-21 Blue Therapeutics, Inc. Methods of treating irritable bowel syndrome

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4192883A (en) 1976-04-09 1980-03-11 Pierre Fabre, S.A. Amides of pyrrolidinoethylamine which can be used in lung therapy
FR2421891A1 (fr) 1977-10-17 1979-11-02 Fabre Sa Pierre Obtention industrielle d'amides de la pyrrolidine ethyl amine
US4663343A (en) 1985-07-19 1987-05-05 Warner-Lambert Company Substituted naphthalenyloxy-1,2-diaminocyclohexyl amide compounds
US4760069A (en) 1985-09-23 1988-07-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4889860A (en) 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
GB8601796D0 (en) 1986-01-24 1986-02-26 Zambeletti Spa L Compounds
JPH02138254A (ja) 1988-02-23 1990-05-28 Glaxo Group Ltd 複素環誘導体
US5232978A (en) 1988-12-23 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung 1-(2-arylethyl)-pyrrolidines
DE3935371A1 (de) 1988-12-23 1990-07-05 Merck Patent Gmbh Stickstoffhaltige ringverbindungen
DE4034785A1 (de) 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
US5389686A (en) 1989-02-20 1995-02-14 Jouveinal Sa Analgesic properties of fedotozine
DE3916663A1 (de) 1989-05-23 1990-11-29 Bayer Ag Substituierte (chinolin-2-yl-methoxy)phenyl-acyl-sulfonamide und -cyanamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
CA2021817C (en) 1989-07-24 2000-09-26 William J. Mork Upholstered article of furniture with interchangeable seating module
DE69029861T2 (de) 1989-11-24 1997-07-10 Smithkline Beecham Spa N-acyl-substituierte azazyklische verbindungen, verfahren zu deren herstellung und deren verwendung als arzneimittel
GB8926560D0 (en) 1989-11-24 1990-01-17 Zambeletti Spa L Pharmaceuticals
US5300687A (en) 1991-07-18 1994-04-05 Ortho Pharmaceutical Corporation Trifluoromethylbenzylphosphonates useful in treating osteoporosis
DE4215213A1 (de) 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide
DE4425071C2 (de) 1994-07-15 1996-08-29 Degussa Verfahren zur Herstellung optisch aktiver Pyrrolidine mit hoher Enantiomerenreinheit
DE19523502A1 (de) 1995-06-28 1997-01-02 Merck Patent Gmbh Kappa-Opiatagonisten für entzündliche Darmerkrankungen
DE19531464A1 (de) 1995-08-26 1997-02-27 Merck Patent Gmbh N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid
ES2252865T3 (es) 1997-09-26 2006-05-16 Noven Pharmaceuticals, Inc. Composiciones bioadhesivas y metodos para la administracion topica de agentes activos.
US20010051181A1 (en) 1997-12-22 2001-12-13 Van Osdol William W. Novel formulations for the transdermal administration of asimadoline
DE19827633A1 (de) 1998-04-20 1999-10-21 Merck Patent Gmbh Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
JP2000080047A (ja) 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
DE69929996T2 (de) 1998-06-30 2006-11-16 Takeda Pharmaceutical Co. Ltd. Pharmazeutisches mittel zur behandlung von diabetes
DE19849650A1 (de) * 1998-10-29 2000-05-04 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung des Irritable Bowel Syndroms (IBS)
DE60018225T2 (de) 1999-03-01 2005-12-29 Pfizer Products Inc., Groton Oxamsäuren mit einer Cyanogruppe als Liganden für den Thyroidrezeptor
US20020025948A1 (en) 2000-06-23 2002-02-28 Banks Bernard Joseph 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GB0015562D0 (en) 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6262062B1 (en) 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6569449B1 (en) 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
DE10116978A1 (de) 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
US6780891B2 (en) 2001-11-30 2004-08-24 Sepracor Inc. Tramadol analogs and uses thereof
EP2074997A1 (en) * 2002-05-17 2009-07-01 Tioga Pharmaceuticals, Inc. Use of Asimadoline for the treatment of digestive disorders
MXPA05002983A (es) * 2002-09-18 2005-06-22 Univ Missouri Analogos de opiato selectivos del receptor opioide d.
DE10259245A1 (de) 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
BRPI0409128A (pt) * 2003-04-08 2006-03-28 Progenics Pharm Inc uso de antagonistas de opióides periféricos, especialmente metilnaltrexona para tratar sìndrome de intestino irritável
SI2368553T1 (sl) 2003-04-08 2015-05-29 Progenics Pharmaceuticals, Inc. Farmacevtske formulacije, vsebujoče metilnatrekson
WO2005016244A2 (en) * 2003-06-13 2005-02-24 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20080090859A1 (en) * 2003-10-30 2008-04-17 Tioga Pharmaceuticals, Inc. Use of Selective Opiate Receptor Modulators In the Treatment Of Neuropathy
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
CA2682608A1 (en) 2007-03-30 2008-10-09 Tioga Pharmaceuticals, Inc. Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome

Also Published As

Publication number Publication date
KR20100016004A (ko) 2010-02-12
US7960429B2 (en) 2011-06-14
DK2136801T3 (da) 2012-12-17
WO2008121496A1 (en) 2008-10-09
US8877800B2 (en) 2014-11-04
CN102641265A (zh) 2012-08-22
US20110046174A1 (en) 2011-02-24
EP2636407A2 (en) 2013-09-11
KR101208326B1 (ko) 2012-12-05
AU2008232954A2 (en) 2011-12-01
EP2561870A1 (en) 2013-02-27
CY1113317T1 (el) 2016-04-13
HK1139860A1 (en) 2010-09-30
JP5416085B2 (ja) 2014-02-12
EP2136801A4 (en) 2010-05-26
AU2008232954A1 (en) 2008-10-09
US20080242720A1 (en) 2008-10-02
JP2010523492A (ja) 2010-07-15
HRP20120798T1 (hr) 2012-11-30
PT2136801E (pt) 2012-12-06
IL201226A0 (en) 2010-05-31
ES2393815T3 (es) 2012-12-28
CN101677997A (zh) 2010-03-24
SI2136801T1 (sl) 2013-01-31
CA2682608A1 (en) 2008-10-09
JP2013173790A (ja) 2013-09-05
EP2136801A1 (en) 2009-12-30
EP2136801B1 (en) 2012-08-29
KR20120058614A (ko) 2012-06-07
MX2009010409A (es) 2010-03-29
EP2636407A3 (en) 2013-11-06
CN101677997B (zh) 2012-05-09
RU2441655C2 (ru) 2012-02-10
PL2136801T3 (pl) 2013-01-31
BRPI0809651A2 (pt) 2014-10-07
RU2009140042A (ru) 2011-05-10

Similar Documents

Publication Publication Date Title
KR101263225B1 (ko) 설사－우세형 및 교대형 과민성 장 증후군의 치료를 위한 카파－아편제 작용제
US11285139B2 (en) Treatment of CNS conditions
JP4249415B2 (ja) Ｃｎｓ疾患の治療のためのピロリジンアセトアミド誘導体単体又は組み合わせ物
JP6014702B2 (ja) 線維筋痛症候群の長期治療のためのミルナシプラン
EP3272343B1 (en) Tapentadol for preventing and treating depression and anxiety
HUE029677T2 (hu) Készítmények centrálisan mediált émelygés és hányás kezelésére
JP2024524434A (ja) うつ状態を処置するための方法
US20110237602A1 (en) Method for treating schizophrenia and related diseases
RU2307651C2 (ru) Каппа-опиатные агонисты для лечения заболеваний мочевого пузыря
JP2011517678A (ja) 過活動膀胱の治療のためのウデナフィル、およびアルフゾシンまたはオキシブチニンの組み合わせの使用
HK1139860B (en) Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20160507

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20160507

St.27 status event code: N-4-6-H10-H13-oth-PC1903